With the new funds, Auxilius will be able to further develop its flagship project involving introduction of Value Added Medication cardiological drug to the US market, in line with the regulatory plan approved by the FDA earlier on this year. The Company continues to screen the market and build a pipeline of other medicinal products where it can add value to patients.